BioCentury
ARTICLE | Clinical News

ENMD begins Phase II studies of 2ME2 in multiple myeloma

December 6, 2000 8:00 AM UTC

EntreMed began a Phase II trial of 2-methoxyestradiol ( 2ME2) in patients with stabilized or relapsed multiple myeloma. The compound, which inhibits both angiogenesis and cell proliferation, is also i...